Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2
The development of a bioartificial pancreas (BAP) with immunoisolating fashion has been gaining attention as a new method for treating diabetes. We have been proceeding with the development of a bag-type BAP that can be easily implanted and that allows for the optional injection or rejection of cell...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2009-05-01
|
Series: | Cell Transplantation |
Online Access: | https://doi.org/10.1177/096368970901805-625 |
id |
doaj-398ebcb3acdf4f0cb275f94686ac522c |
---|---|
record_format |
Article |
spelling |
doaj-398ebcb3acdf4f0cb275f94686ac522c2020-11-25T02:48:36ZengSAGE PublishingCell Transplantation0963-68971555-38922009-05-011810.1177/096368970901805-625Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2Takeshi Yuasa0Jorge D. Rivas-Carrillo1Nalú Navarro-Alvarez2Alejandro Soto-Gutierrez3Yasuhiro Kubota4Yasuhiko Tabata5Teru Okitsu6Hirofumi Noguchi7Shinichi Matsumoto8Shuhei Nakaji9Noriaki Tanaka10Naoya Kobayashi M.D., Ph.D.11Department of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, JapanDepartment of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, JapanDepartment of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, JapanDepartment of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, JapanDepartment of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, JapanDepartment of Organ Reconstruction and Biomaterials, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, JapanDepartment of Transplant Surgery, Kyoto University Hospital, Kyoto 606-8507, JapanDepartment of Biomedical Engineering, Okayama University of Science, Okayama 700-0005, JapanDepartment of Biomedical Engineering, Okayama University of Science, Okayama 700-0005, JapanDepartment of Biomedical Engineering, Okayama University of Science, Okayama 700-0005, JapanDepartment of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, JapanDepartment of Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, JapanThe development of a bioartificial pancreas (BAP) with immunoisolating fashion has been gaining attention as a new method for treating diabetes. We have been proceeding with the development of a bag-type BAP that can be easily implanted and that allows for the optional injection or rejection of cells at any time. If fibrosis develops around a BAP device, then the permeability of substances transmitted through a semipermeable membrane will decrease, thereby reducing the reactivity with glucose, so it is necessary for the material of the device to have an excellent histocompatibility. Furthermore, in order to improve the efficacy of BAP treatment, it is important to maintain an environment of ample blood flow around the device. We have created a bag-type device for BAP that is 20 × 20 mm in size and comprises two layers of membranes. We have used an EVAL membrane for the outer membrane of the two layers. The EVAL membrane is a semipermeable membrane with good insulin permeability, which functions as an immunoisolation membrane. The inner membrane consists of PAU-coated HD-PE (nonwoven material processed with polyaminourethan) and it is designed to function as a scaffold for cells. We used Lewis rats to determine whether the effectiveness of fibroblast growth factor 2 (bFGF) can be improved by concomitantly using bFGF with a capacity for blood vessel regeneration as well as bFGF immersed in a sheet of gelatin. We placed the BAP in the abdominal cavity and covered it with the greater omentum. We were able to significantly increase the blood flow and the number of new blood vessels in the tissue surrounding the BAP device by using gelatinized bFGF. There were only a few instances of fibrosis as a biological reaction to the EVAL membrane, and the infiltration of inflammatory cells was mild. There were no adverse effects related to implantation of the device. We confirmed in this study that the use of an implantable BAP device and bFGF allowed for a better blood flow around the BAP device. There were only minor instances of fibrosis and inflammation reaction around the BAP, thus indicating the BAP that we are currently developing to have an excellent histocompatibility.https://doi.org/10.1177/096368970901805-625 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Takeshi Yuasa Jorge D. Rivas-Carrillo Nalú Navarro-Alvarez Alejandro Soto-Gutierrez Yasuhiro Kubota Yasuhiko Tabata Teru Okitsu Hirofumi Noguchi Shinichi Matsumoto Shuhei Nakaji Noriaki Tanaka Naoya Kobayashi M.D., Ph.D. |
spellingShingle |
Takeshi Yuasa Jorge D. Rivas-Carrillo Nalú Navarro-Alvarez Alejandro Soto-Gutierrez Yasuhiro Kubota Yasuhiko Tabata Teru Okitsu Hirofumi Noguchi Shinichi Matsumoto Shuhei Nakaji Noriaki Tanaka Naoya Kobayashi M.D., Ph.D. Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2 Cell Transplantation |
author_facet |
Takeshi Yuasa Jorge D. Rivas-Carrillo Nalú Navarro-Alvarez Alejandro Soto-Gutierrez Yasuhiro Kubota Yasuhiko Tabata Teru Okitsu Hirofumi Noguchi Shinichi Matsumoto Shuhei Nakaji Noriaki Tanaka Naoya Kobayashi M.D., Ph.D. |
author_sort |
Takeshi Yuasa |
title |
Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2 |
title_short |
Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2 |
title_full |
Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2 |
title_fullStr |
Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2 |
title_full_unstemmed |
Neovascularization Induced around an Artificial Device Implanted in the Abdomen by the Use of Gelatinized Fibroblast Growth Factor 2 |
title_sort |
neovascularization induced around an artificial device implanted in the abdomen by the use of gelatinized fibroblast growth factor 2 |
publisher |
SAGE Publishing |
series |
Cell Transplantation |
issn |
0963-6897 1555-3892 |
publishDate |
2009-05-01 |
description |
The development of a bioartificial pancreas (BAP) with immunoisolating fashion has been gaining attention as a new method for treating diabetes. We have been proceeding with the development of a bag-type BAP that can be easily implanted and that allows for the optional injection or rejection of cells at any time. If fibrosis develops around a BAP device, then the permeability of substances transmitted through a semipermeable membrane will decrease, thereby reducing the reactivity with glucose, so it is necessary for the material of the device to have an excellent histocompatibility. Furthermore, in order to improve the efficacy of BAP treatment, it is important to maintain an environment of ample blood flow around the device. We have created a bag-type device for BAP that is 20 × 20 mm in size and comprises two layers of membranes. We have used an EVAL membrane for the outer membrane of the two layers. The EVAL membrane is a semipermeable membrane with good insulin permeability, which functions as an immunoisolation membrane. The inner membrane consists of PAU-coated HD-PE (nonwoven material processed with polyaminourethan) and it is designed to function as a scaffold for cells. We used Lewis rats to determine whether the effectiveness of fibroblast growth factor 2 (bFGF) can be improved by concomitantly using bFGF with a capacity for blood vessel regeneration as well as bFGF immersed in a sheet of gelatin. We placed the BAP in the abdominal cavity and covered it with the greater omentum. We were able to significantly increase the blood flow and the number of new blood vessels in the tissue surrounding the BAP device by using gelatinized bFGF. There were only a few instances of fibrosis as a biological reaction to the EVAL membrane, and the infiltration of inflammatory cells was mild. There were no adverse effects related to implantation of the device. We confirmed in this study that the use of an implantable BAP device and bFGF allowed for a better blood flow around the BAP device. There were only minor instances of fibrosis and inflammation reaction around the BAP, thus indicating the BAP that we are currently developing to have an excellent histocompatibility. |
url |
https://doi.org/10.1177/096368970901805-625 |
work_keys_str_mv |
AT takeshiyuasa neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT jorgedrivascarrillo neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT nalunavarroalvarez neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT alejandrosotogutierrez neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT yasuhirokubota neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT yasuhikotabata neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT teruokitsu neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT hirofuminoguchi neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT shinichimatsumoto neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT shuheinakaji neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT noriakitanaka neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 AT naoyakobayashimdphd neovascularizationinducedaroundanartificialdeviceimplantedintheabdomenbytheuseofgelatinizedfibroblastgrowthfactor2 |
_version_ |
1724747625984425984 |